Acute decompensated heart failure and cardiogenic shock have had very little drug innovation in decades. The Company believes istaroxime has a profile that offers potential benefits to patients with low blood pressure due to heart failure. Istaroxime improves cardiac function and can increase blood pressure without increasing heart rate. Also, istaroxime tends to preserve measures of renal function and contributes to resolution of congestion and fluid overload that often accompanies heart failure. Important ...

Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses in previous trials The SEISMiC C Study is a global trial including sites in the U.S., Europe and Latin America. It is placebo- controlled, double-blinded study with istaroxime being added to current standard of care, including inotropes or vasopressors in patients with more severe cardiogenic shock (SCAI stage C) ...

Core Insights - Istaroxime is a first-in-class dual-mechanism therapy aimed at treating acute heart failure (AHF) and has shown positive results in Phase 2 studies [3] - The United States Patent and Trademark Office has granted a patent for istaroxime, which will provide protection until 2039 if approved for AHF [1][2] - Windtree Therapeutics is focused on becoming a revenue-generating company across multiple growing industries [4] Company Overview - Windtree Therapeutics, Inc. is a diversified company with a focus on revenue generation and profitability in various industries [4] - The company is advancing istaroxime towards Phase 3 readiness for cardiogenic shock and AHF [2] Product Details - Istaroxime improves both systolic and diastolic cardiac function, increasing myocardial contractility and facilitating myocardial relaxation [3] - Clinical data indicates that istaroxime can significantly enhance cardiac function and blood pressure without raising heart rate or causing significant cardiac rhythm disturbances [3]

Core Insights - Windtree Therapeutics is advancing its istaroxime cardiogenic shock program with the SEISMiC C Study, targeting interim analysis results for July 2025 [1][2][3] - Istaroxime is a first-in-class dual-mechanism therapy aimed at improving cardiac function in patients with cardiogenic shock [4] Company Overview - Windtree Therapeutics focuses on developing innovative therapies for critical conditions and aims to become a revenue-generating company [5] - The company's product portfolio includes istaroxime, which is in Phase 2 trials for acute heart failure and cardiogenic shock, as well as preclinical candidates for heart failure and oncology applications [5] Study Details - The SEISMiC C Study is a global, placebo-controlled, double-blinded trial assessing the efficacy of istaroxime in addition to standard care [2] - The primary endpoint is the systolic blood pressure profile over the first six hours, with additional measurements including cardiac function and treatment failure rates [2] Clinical Significance - Interim data from the SEISMiC C Study will provide insights into istaroxime's physiological impact and safety profile in more severely ill patients [3] - Previous Phase 2 studies have shown that istaroxime can significantly improve cardiac function and blood pressure without increasing heart rate or causing significant rhythm disturbances [4]